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Abstract 
In December 2019, a conference entitled “Europe That Protects: Safeguarding Our Planet, Safeguarding Our Health” 
was held in Helsinki. It was co‑organized by the Finnish Institute for Health and Welfare, the Finnish Environment 
Institute and the European Commission, under the auspices of Finland’s Presidency of the EU. As a side event, a 
symposium organized as the final POLLAR (Impact of air POLLution on Asthma and Rhinitis) meeting explored the 
digital transformation of health and care to sustain planetary health in airway diseases. The Finnish Allergy Programme 
collaborates with MASK (Mobile Airways Sentinel NetworK) and can be considered as a proof‑of‑concept to impact 
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Introduction
Most economies are struggling to deliver cost-effective, 
high-quality healthcare. There is an urgent need for the 
healthcare system to leverage developments in digital 
health in order to improve cost-effectiveness [1]. The 
term “digital health” includes advanced medical technol-
ogies, disruptive innovations and digital communication 
tools aiming to provide best practices [2, 3].
A conference entitled “Europe That Protects: Safe-
guarding Our Planet, Safeguarding Our Health” was 
based on the new concept of the interactions between 
human health and the health of the planet. It brought 
stakeholders together, including researchers, policy mak-
ers and regulators. The aim was to identify and discuss (i) 
the scientific challenges for harvesting and enhancing the 
benefits of a sound environment for human health, and 
(ii) the challenges to overcome environmental threats to 
human health [4]. The main outcome consisted of rec-
ommendations on research and innovation priorities for 
the EU and Member States to enable collaborative work 
to protect both human health and our planet. This event 
was co-organized by the Finnish Institute for Health and 
Welfare, the Finnish Environment Institute and the Euro-
pean Commission, under the auspices of Finland’s Presi-
dency of the EU in 2019.
The aim of POLLAR (Impact of Air POLLution on 
Asthma and Rhinitis, EIT Health) [5, 6] is to combine 
emerging technologies in order to understand the effect 
of air pollution on allergic rhinitis and its impact on 
sleep, work and asthma. The objective is to propose novel 
care pathways at the EU level integrating online pollution 
data and symptoms of allergy in the already existing sen-
tinel network.
During this conference, a symposium organized as the 
final POLLAR meeting was held to explore the digital 
transformation of health and care—using airway diseases 
as an example—and how it relates to planetary health. 
Implementation of the messages and goals of the Finnish 
Allergy Programme 2008–2018 was shown as a model, 
which could be further enhanced by the digital transfor-
mation of health.
Planetary Health
In 2015, a new approach called “Planetary Health” was 
proposed by a Rockefeller Foundation-Lancet Commis-
sion. Planetary Health was defined as the achievement 
of the highest attainable standard of health, wellbeing 
and equity worldwide through judicious attention to the 
human systems—political, economic and social—that 
shape Earth’s natural system limits within which human-
ity can flourish [7, 8]. Since its inception, the Planetary 
Health approach has received substantial attention with 
an increasing presence in the academic community.
However, how to deploy the Planetary Health approach 
in the health care system remains a challenge. First, the 
health care system needs to join the societal efforts to 
drastically cut  CO2 emissions in order to reach the goal 
of the Paris agreement. The Intergovernmental Panel on 
Climate Change (IPCC) 1.5º report in 2018 claimed that 
current emission needs to be reduced by 40% in 2030 and 
should be reduced to zero by 2050. There is a large poten-
tial for health care systems contributing to these goals. 
The adoption of Planetary Health in health care and pub-
lic health services can be facilitated by identifying the 
strategies that result in clear interactions between human 
health and the health of the Planet.
Some examples can be proposed for respiratory dis-
eases. Smoking, which is one of the leading causes of 
preventable mortality worldwide with 7 million deaths 
annually, has been shown to be a relevant cause of envi-
ronmental degradation due to deforestation, intensive 
use of pesticides and other poor environmental practices. 
Green-house emissions, caused by cultivating tobacco, 
correspond to the full emissions of some single countries 
[9, 10]. Health care and technology can be considered 
good for health (assuming appropriate use) but it has a 
significant negative impact on the planet. In Australia, it 
accounts for about 7% of all  CO2 emissions, mainly attrib-
utable to hospitals and medicines [11]. Regarding res-
piratory and allergic diseases, the Environmental Audit 
Committee of the UK parliament has requested that by 
2022 at least 50% of prescribed inhalers should be of low 
global warming potential (GWP) [12]. Planting trees in a 
Planetary Health. The Good Practice of DG Santé (The Directorate‑General for Health and Food Safety) on digitally‑
enabled, patient‑centred care pathways is in line with the objectives of the Finnish Allergy Programme. The ARIAC‑
ARE‑Digital network has been deployed in 25 countries. It represents an example of the digital cross‑border exchange 
of real‑world data and experience with the aim to improve patient care. The integration of information technology 
tools for climate, weather, air pollution and aerobiology in mobile Health applications will enable the development 
of an alert system. Citizens will thus be informed about personal environmental threats, which may also be linked to 
indicators of Planetary Health and sustainability. The digital transformation of the public health policy was also pro‑
posed, following the experience of the Agency for Health Quality and Assessment of Catalonia (AQuAS).
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city is good for human and planetary health but planting 
allergenic trees is not good for human health. These and 
other examples show how health care and public health 
can adopt a Planetary Health transformative strategy and 
contribute to stopping global warming and the loss of 
natural resources in which human health can sustainably 
progress.
However, how to bring the potential of the planetary 
health strategies to the digital transformation of health 
care is a challenge. Currently, there are multiple apps for 
capturing either dietary or travel behaviour and estimat-
ing the associated carbon cost. However, most of these 
apps focus on one or a few individual issues like travel or 
diet and are of mixed quality [13].
The POLLAR effort to bring both air pollution and 
pollen season data to a digital application, along with 
information of symptoms and medication followed by 
allergy patients, is a new innovation. The data can be fur-
ther supplemented by climate models and forecasts. The 
integration of data from different sources and a new kind 
of modelling for personal use can improve the health of 
patients and spread information needed for action to 
sustain planetary health. The idea, with disease specific 
information and data collecting, might be scalable for 
many other non-communicable diseases.
Deployment of the Finnish Allergy Programme, 
a proof‑of‑concept to impact Planetary Health
The Finnish Allergy Programme (2008–2018) revisited 
the allergy and asthma paradigm by turning avoidance 
strategy into tolerance/resilience strategy and improving 
nature relatedness [14, 15].
Environmental and lifestyle factors are responsible for 
most of the so-called allergy and asthma epidemic since 
the second world war. That is why immune tolerance and 
allergy health were promoted through a Nature Step in 
resetting the connection between humans and the natu-
ral environment [16]. Promoting physical activity, reduc-
ing air pollution and stopping smoking were also central. 
Both primary and secondary (tertiary) prevention were 
in focus.
The 10-year programme defined goals, tools and meas-
ures as well as follow-up of outcome. A long-term edu-
cational campaign was implemented both for healthcare 
professionals and the lay public. The burden of allergy 
and asthma in Finland started to decline with less medi-
calisation, fewer allergy diets, less severe asthma, and 
fewer costs [17]. The Finnish experience can be deployed 
in European Union countries having efficient and acces-
sible public healthcare. The good educational level of citi-
zens allows new information to penetrate effectively. The 
key words are: motivate and organize. Do not develop 
anything, be precise: say what you are going to do, by 
what means, and how you are going to follow the out-
come. The allergy and asthma burden can be reduced, 
and very likely the burden of many other non-communi-
cable diseases which are on the rise everywhere in urban 
societies. Promoting public health also goes together 
with the safeguarding of our planet [7]. The Finnish 
Allergy Programme is sustaining planetary health by 
many aspects (Table 1).
The MASK digital transformation of health 
and care for airway diseases
Over the past 20  years, ARIA (Allergic Rhinitis and its 
Impact on Asthma) [18] has evolved, with strong politi-
cal commitment, from the first multi-morbidity guideline 
in respiratory diseases to a proof-of-concept of the digital 
transformation of health and care for the management of 
patients with long-term conditions.
As a proof-of-concept for chronic disease care, MASK, 
the Phase 3 ARIA project [19, 20], in collaboration with 
professional and patient organizations in the field of 
allergy and airway diseases, is proposing real-life inte-
grated care pathways (ICPs) centred around the patient 
with rhinitis and asthma multi-morbidity. These next-
generation ICPs represent a prism through which the 
potential for digitally transforming healthcare can be 
Table 1 Potential of the Finnish Allergy Programme to address Planetary Health
Finnish Allergy Programme Impact on Planetary Health
Endorse health, not allergy Endorse the Planet
Improve contact with nature Contribute to conserving and regenerating nature
Strengthen tolerance/resilience Understand and strengthen the role of biodiversity
Avoid allergens only if mandatory Promote Planet sustainable diets
Prevent allergies Reduce the planetary impact of medical treatments and harm‑
ful chemicals in planet to human, human to planet chain
Recognize and treat severe allergies early Reduce the planetary impact of avoidable health care wastage
Improve air quality Reduce air pollution, both outdoors and indoors
Stop smoking Eradicate smoking and its environmental impacts
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viewed. MASK is a Good Practice of DG Santé on digi-
tally-enabled, patient-centred ICPs [21].
Although environmental factors play a major role 
in allergic diseases, they have never been included in 
guidelines or recommendations. Based on the results of 
POLLAR [5], ARIA next-generation ICPs are embed-
ding exposure to environmental factors such as pollen 
and air pollution. Furthermore, novel approaches such as 
artificial intelligence are being used. As there is increas-
ing evidence that patients’ choices and behaviours have 
an impact on the Planet, this will be the background of 
ARIA Planetary Health [7].
Next‑generation care pathways for allergic rhinitis
ICPs are structured multi-disciplinary care plans detail-
ing the key steps of patient care [22]. They promote the 
translation of guideline recommendations into local pro-
tocols and their application to clinical practice. ICPs have 
been proposed with a focus on mHealth technologies 
that should enhance self-management and adherence to 
guidelines and ICPs. They represent an important topic 
of the digital transformation of health and care.
Next-generation care pathways for allergic rhinitis rep-
resent an innovative digitally-enabled, patient-centred 
approach for ICPs [23]. They have been proposed by 
ARIA Phase 4 for rhinitis and asthma multi-morbidity 
to be scaled up to chronic diseases. Five aspects of ICPs 
have particularly been developed (Fig. 1).
1. Self-care: Patient participation, health literacy  and 
self-care through technology-assisted patient activa-
tion [25].
2. Pharmacist: Most patients with allergic rhinitis use 
OTC medications and a guide for the pharmacist, 
already proposed by ARIA in 2004 [26], has been 
updated [27]. A pocket guide is pending.
3. ICPs for allergen immunotherapy [28]: Only guide-
lines for AIT were previously proposed. This is the 
first ICP. The ARIA-EAACI pocket guide is available.
4. The next-generation guidelines for allergic rhinitis 
have assessed GRADE recommendations in AR and 
asthma using real-world evidence (RWE) [23]. RWE 
includes not only randomized-controlled trials on 
treatment effects, but also real-world data (RWD) 
obtained by mHealth tools—including MASK—and 
chamber studies [29] in order to confirm effective-
ness or refine current recommendations [30]. MASK 
results were used to refine the GRADE guidelines 
[31]. This appears to be the first attempt to test 
GRADE recommendations with RWE.
5. It is very important to include non-medical interven-
tions in ICPs, such as feeding cats with egg produced 
anti-Fel d1antibodies to reduce their allergenicity 
[32].
The Impact on Planetary Health represents the sixth 
approach. Several aspects of Planetary Health are 
included in next-generation ICPs—such as biodiversity, 
Fig. 1 Next‑generation care pathways integrating Planetary Health sustainability (from [24])
Page 5 of 9Bousquet et al. Clin Transl Allergy           (2020) 10:24  
exercise, air pollution and aerobiology—but also actions 
by municipalities to improve human and Planetary 
Health (e.g. the ECARF action plan in Berlin). The POL-
LAR predictive model of pollen seasons and air pollution 
index are one of the examples.
These next-generation ICPs have been used to develop 
value added medicine.
The Finnish Allergy Programme goals are in line with 
many results of the MASK (Mobile Airways Sentinel 
NetworK) digital platform on allergies and asthma [19] 
(Table 2).
ARIACARE centres of excellence
In ARIA Phase 4 (change management for airway dis-
eases) [21, 38], a network of centres of excellence (CoE) 
is being organized.  GA2LEN ARIACARE is part of the 
 GA2LEN CoE that already includes UCARE (for urti-
caria) and ADCARE (for atopic dermatitis) [39]. Accredi-
tation follows the UCARE proposals, and ARIA members 
will be able to apply. Other groups will also be able to join 
ARIACARE.
ARIACARE-Digital is a novel network with the aim to 
implement the digital transformation of health and care 
in airway diseases. Both members of MASK and oth-
ers can join this network. ARIACARE-Digital is being 
developed with EAACI and has links with  GA2LEN but 
is independent. Three levels are proposed for these cen-
tres (regular, gold and platinum) with a review each year. 
Numerous benefits are expected from this innovation.
Digital health  is progressing towards more interoper-
ability for the digital cross border exchange of health data 
in Europe. The ARIACARE-Digital network is already 
deployed in 25 countries around the world using the 
same standard operating procedures (SOPs) for allergic 
diseases and asthma and represents a proof-of-concept 
for digital cross-border exchange.
Citizens’ views on the respiratory targets 
of planetary health
Patients with respiratory disease are the sentinels of 
air quality since poor air quality indoors and outdoors 
directly impacts their disease and can cause or exacerbate 
respiratory allergy, asthma or COPD. Therefore, together 
with pulmonary and public health doctors, they have 
been the first advocates for the right to clean air and bet-
ter air quality standards. People with asthma and COPD 
in Europe state that their top priority is for governments 
to do more regarding air pollution [40]. Recently, the 
whole society, in particular young people, have become 
aware and risen up to combat climate change. According 
to WHO, air pollution needs to be at the core of the cli-
mate change action [41]. However, people’s health is not 
sufficiently put at the core of planetary health as being 
inherently interlinked. Health is among the top priori-
ties for European citizens at national level and, for both 
EU and national level, concerns regarding climate change 
and environment are on the rise [42]. The “Green Deal” 
is one of the top priorities for the new European Com-
mission [43]. The Finnish Council Presidency priority for 
Economy of Wellbeing integrates “health in all policies” 
[44].
Table 2 Set‑up goals for health care of the Finnish Allergy Programme and digital health
Goals Indicators Digital transformation of health: MASK
Prevent allergy Asthma, rhinitis and atopic eczema preva‑
lence reduced 20%
Improve tolerance Food allergy diets in day‑care and schools 
reduced 40%
Cat food containing anti‑Fel d1 may help 
to keep cats at the homes of allergic 
patients
[32]
Improve allergy diagnostics Skin testing (prick and patch tests) in 
certified testing centres
A screening test for asthma, COPD and 
rhinitis helps in the diagnosis of allergies 
and in sending the patients to certified 
allergy centres
[33], in preparation
Reduce work‑related allergies Occupational allergies (asthma, rhinitis, 
contact dermatitis) reduced 40%
Daily VAS work assessment [34]
Focus on severe allergies and treat in time Good allergy practice defined, asthma 
emergency visits reduced 40%
MASK: Good Practice of DG Santé
Adherence to treatment*
Efficacy of medications*
Next‑generation care pathways
Next‑generation guidelines*
Value added medicine*
(*: proof‑of‑concept in rhinitis)
[21]
[31, 35]
[31, 36]
[24, 28]
[24, 28]
Reduce allergy and asthma costs Allergy‑related total costs (direct and 
indirect) reduced 10%
EQ‑5D, WPAI‑AS [37]
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Technological developments enable personal monitor-
ing for air pollution—including pollen—combined with 
disease management. Citizens have become active actors 
for the environment, as well as for their personal health.
Planetary and human health go together, and citizens, 
no longer only patients, are at the core of this change. The 
digital transformation of healthcare to improve adher-
ence and patient and citizen participation is here. How-
ever, the healthcare systems are falling behind, as citizens 
are leading with the use of apps.
There is an opportunity for interlinking individual and 
respiratory health to planetary health.
Integration of IT tools with citizen science 
to promote Planetary Health
Citizen science represents a way of engaging citizens in 
science and of empowering them to understand, prior-
itize and tackle society challenges by co-creating scien-
tific results that lead to new knowledge and action [45]. 
Citizens’ interests, creativity, diversity and experience 
can contribute with new ideas and can help to promote 
new research areas or existing ones that are closer to citi-
zens’ interests. Still, many citizen science projects basi-
cally count on citizens just as data providers. An increase 
in projects with the highest involvement of citizens, 
including orienting research questions, has the potential 
to contribute to Planetary Health. Actually, many citizen 
science projects have dealt with environmental issues, 
especially environmental monitoring, showing an under-
lying interest of citizens in protecting the planet [46].
Likewise, citizens are concerned by their health, as 
shown by the increase of health monitoring with apps 
and sensors. The availability of new cheap sensors and 
apps for environmental monitoring and for measuring 
health parameters, like the Allergy Diary—MASK-air 
App [19], facilitates the creation of new citizen science 
studies linking environment and health. However, such 
studies face extra challenges compared to other citi-
zen science projects [47]. Some of these challenges will 
be discussed during the presentation. These include the 
need for ethical approvals and informed consent forms; 
potential biases due to non-representativeness or self-
selection; that public health issues are  usually topics of 
public dispute; how to ensure that citizens have adequate 
competencies and capabilities to conduct the work and 
that the data collected and the inference made with it 
have sufficient quality. In addition, is important to man-
age citizens’ expectations, as they may expect solutions to 
a problem (not always possible), the study may produce 
unexpected or null results, and anyway the evidence from 
a single study is definitive and should be weighed with 
other available evidence.
Integration of IT tools for climate, weather, air 
pollution and aerobiology
There are several models and integration technologies 
that bring together the key drivers of human pollen-
related allergy and asthma. They include meteorological 
models, atmospheric composition and air quality mod-
els, pollen prediction models, pollen real-time monitor-
ing techniques, and the mobile applications interacting 
with the allergy sufferers, collecting their self-assessment 
reports and delivering forecasts of their personalized 
allergy risk.
The POLLAR system is constructed around the MASK-
air mobile application and its allergy symptom database. 
It is integrated with the Symptom Forecasting Model 
developed within the PASYFO (Personalized Allergy 
Symptoms Forecasting System) project of Copernicus 
Atmospheric Monitoring Service, which also supplies 
the meteorological, air quality and pollen information 
for Europe. Additional pollen and global air quality fore-
casts are generated by the SILAM (System for integrated 
modelling of atmospheric composition) model of the 
Finnish Meteorological Institute (FMI) [48–50]. Another 
novel component is real-time pollen monitoring, which 
is emerging in several European countries and being 
established also in Finland within the PS4A project of the 
Academy of Finland.
The key outcome of the system—the allergy risk fore-
casts based on the patients’ self-assessment and fore-
casts of environmental parameters—was established a 
few years ago as the basis of the forecasting setup of the 
system. It has recently been developed for POLLAR and 
embedded in the MASK app.
Digital transformation in the health public policy
The Agency for Health Quality and Assessment of Cat-
alonia (AQuAS) aims to carry out data evaluation and 
analysis to generate relevant and reliable information, 
promoting health and enhancing the sustainability of the 
Catalan health system. AQuAS has supported the Min-
istry of Health decision-making for better performance 
in safety, efficacy and efficiency, e.g. of public procure-
ment. This has been done mainly by innovative health 
data analysis, health technology assessment and citizens’ 
or professionals’ consultations.
The Agency leads a strategical project on data analysis, 
the Public Data Analysis Program for Health Research 
and Innovation (PADRIS, http://aquas .genca t.cat/en/
ambit s/anali tica-dades /padri s/). A multidisciplinary 
team provides community health data of 7.5 million 
citizens, adding value through data to research, innova-
tion and health assessment. According to the legal and 
regulatory framework, ethical principles and transpar-
ency, the programme provides access to anonymized 
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data for around 50 public projects every year. Real 
World Data is generated by all health providers from 
the Catalan health service and stored on the Integrated 
Catalan health data system, known as SISCAT (Sistema 
sanitari integral d’utilització pública de Catalunya, 
http://sac.genca t.cat/sacge ncat/AppJa va/organ igram 
a.jsp?codi=2803&jq=20004 0).
PADRIS is also an initiative positioning Catalonia in the 
international information society arena, moving towards 
a new specialized care model to promote research and 
transfer the results to clinical practice.
Findings of observational studies, RWE and registry 
data all require judicious evaluation when used to assess 
treatment effects. Health care decisions improve if this 
data reservoir provides insights beyond those addressed 
by randomized controlled trials.  Due to the need of 
clinical decision support tools, the use of RWE has been 
essential. Catalonia is currently using RWD for evidence 
based decision making in different scenarios from the 
management to the clinical level. One remarkable case 
is the predictive model for the monitoring of epidemic 
seasons in Catalonia. Predictive mathematic models have 
been used for the potential early detection of epidemic 
patterns. Some examples are: the real-time predictive 
seasonal influenza model, developed by the Public Health 
Agency of Catalonia, and the asthma predictive seasonal 
model, which is currently being explored by AQuAS.
The real-time spatial predictive model of the ILI 
(Influenza Like Illness) incidence rate in Catalonia pro-
vides 1- and 2-week forecasts. These include historical 
and real-time data from different sources: the statutory 
reporting disease system, the flu sentinel surveillance 
system, the official meteorology service, microbiology 
diagnostics data and Google Flu Trends. The model is a 
useful decision-making tool although evaluation is diffi-
cult due to uncertainty. The accuracy of prediction at 1 
and 2 weeks was above 80% globally, but was lower dur-
ing the peak epidemic period [51].
Asthma is a common chronic respiratory condition in 
Spain, with a prevalence of 5% in adults and 10% in chil-
dren. The vast majority of cases are diagnosed during 
childhood and 60–75% of asthma cases have an allergic 
origin.
In order to tackle the asthma epidemic, AQuAS is 
exploring a new predictive model oriented to health sys-
tems decision making. The aim is to design an algorithm 
to predict asthma peaks within time and space and to 
quantify the temporal patterns for acute symptoms. The 
model will integrate data from SISCAT clinical health 
records from 2008 to 2018, historical and real-time data 
from the electronical drug prescription registry as well 
as  meteorological data. This kind of RWD predictive 
tool returns value to the Catalan society. It offers the 
opportunity to design preventive measures, plan health-
care needs, improve patient outcomes, and guide new 
research solutions.
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